Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 57Recruiting 21Terminated 17Active not recruiting 11Unknown 8Withdrawn 5Not yet recruiting 2

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

Gemcitabine 2Docetaxel 2Cyclophosphamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2pembrolizumab 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Sarcoma, Synovial × Clear all
NCT05116800 2021-12-07

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Brown University

Phase 2 Withdrawn
Sarcoma

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04906876 2021-07-28

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Brown University

Phase 2 Withdrawn
Sarcoma

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

GlaxoSmithKline

Phase 2 Withdrawn
Sarcoma

Neoplasms, Sarcoma, Synovial

NCT03773510 2019-05-13

TRADITIONS

Italian Sarcoma Group

Phase 3 Withdrawn
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial

NCT02059850 2016-02-03

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
Sarcoma

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡